Literature DB >> 24190934

Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study.

Lucy C Chappell1, Suzy Duckworth, Paul T Seed, Melanie Griffin, Jenny Myers, Lucy Mackillop, Nigel Simpson, Jason Waugh, Dilly Anumba, Louise C Kenny, Christopher W G Redman, Andrew H Shennan.   

Abstract

BACKGROUND: Hypertensive disorders of pregnancy are a major contributor to death and disability for pregnant women and their infants. The diagnosis of preeclampsia by using blood pressure and proteinuria is of limited use because they are tertiary, downstream features of the disease. Placental growth factor (PlGF) is an angiogenic factor, a secondary marker of associated placental dysfunction in preeclampsia, with known low plasma concentrations in the disease. METHODS AND
RESULTS: In a prospective multicenter study, we studied the diagnostic accuracy of low plasma PlGF concentration (<5th centile for gestation, Alere Triage assay) in women presenting with suspected preeclampsia between 20 and 35 weeks' gestation (and up to 41 weeks' gestation as a secondary analysis). The outcome was delivery for confirmed preeclampsia within 14 days. Of 625 women, 346 (55%) developed confirmed preeclampsia. In 287 women enrolled before 35 weeks' gestation, PlGF <5th centile had high sensitivity (0.96; 95% confidence interval, 0.89-0.99) and negative predictive value (0.98; 0.93-0.995) for preeclampsia within 14 days; specificity was lower (0.55; 0.48-0.61). Area under the receiver operating characteristic curve for low PlGF (0.87, standard error 0.03) for predicting preeclampsia within 14 days was greater than all other commonly used tests, singly or in combination (range, 0.58-0.76), in women presenting with suspected preeclampsia (P<0.001 for all comparisons).
CONCLUSIONS: In women presenting before 35 weeks' gestation with suspected preeclampsia, low PlGF has high sensitivity and negative predictive value for preeclampsia within 14 days, is better than other currently used tests, and presents an innovative adjunct to management of such women.

Entities:  

Keywords:  angiogenesis inducers; diagnosis; hypertension; pregnancy

Mesh:

Substances:

Year:  2013        PMID: 24190934     DOI: 10.1161/CIRCULATIONAHA.113.003215

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  92 in total

Review 1.  Molecular Mechanisms of Preeclampsia.

Authors:  Tammy Hod; Ana Sofia Cerdeira; S Ananth Karumanchi
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-20       Impact factor: 6.915

Review 2.  Tracking placental development in health and disease.

Authors:  John D Aplin; Jenny E Myers; Kate Timms; Melissa Westwood
Journal:  Nat Rev Endocrinol       Date:  2020-06-29       Impact factor: 43.330

Review 3.  Anti-angiogenesis and Preeclampsia in 2016.

Authors:  Susanne Schrey-Petersen; Holger Stepan
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

Review 4.  Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis.

Authors:  Kathryn J Gray; Richa Saxena; S Ananth Karumanchi
Journal:  Am J Obstet Gynecol       Date:  2017-11-11       Impact factor: 8.661

Review 5.  Preeclampsia beyond pregnancy: long-term consequences for mother and child.

Authors:  Hannah R Turbeville; Jennifer M Sasser
Journal:  Am J Physiol Renal Physiol       Date:  2020-04-06

Review 6.  Low molecular weight heparin for the prevention of severe preeclampsia: where next?

Authors:  Kelsey McLaughlin; Ralph R Scholten; John D Parker; Enrico Ferrazzi; John C P Kingdom
Journal:  Br J Clin Pharmacol       Date:  2018-01-29       Impact factor: 4.335

7.  Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study.

Authors:  Piya Chaemsaithong; Roberto Romero; Adi L Tarca; Steven J Korzeniewski; Alyse G Schwartz; Jezid Miranda; Ahmed I Ahmed; Zhong Dong; Sonia S Hassan; Lami Yeo; Tinnakorn Tinnakorn
Journal:  J Matern Fetal Neonatal Med       Date:  2014-09-29

8.  Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study.

Authors:  Steven J Korzeniewski; Roberto Romero; Tinnakorn Chaiworapongsa; Piya Chaemsaithong; Chong Jai Kim; Yeon Mee Kim; Jung-Sun Kim; Bo Hyun Yoon; Sonia S Hassan; Lami Yeo
Journal:  Am J Obstet Gynecol       Date:  2015-12-11       Impact factor: 8.661

9.  A Prospective Study of Placental Growth Factor Assay as a Novel Biomarker in Predicting Early-Onset Preeclampsia in High-Risk Patients.

Authors:  Pooja Mathur; Poonam Mathur; Laxmi Maru; Anupama Dave
Journal:  J Obstet Gynaecol India       Date:  2015-11-19

10.  The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Amy E Whitten; Steven J Korzeniewski; Piya Chaemsaithong; Edgar Hernandez-Andrade; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.